antigens . Our findings indicate that both cell lines bear tumor-associated transplantation antigens capable of inducing transplantation immunity in syngeneic hosts. There was, however, no simple relationship between these transplantation antigens and a particular viral antigen.
Materials and Methods
Mice . All mice were from our own colony of highly inbred mouse strains . The congenic mouse strain, BALB .B, was derived from the (BALB/c x C57BL/10)F, cross . 13 consecutive generations of backcrosses to BALB/c were performed, with selection in each generation for the H-2°haplotype of the C57BL/10 parent . The strain was then inbred . Animals were usually 6-10-wk old at the time of inoculation .
Viruses . The variant N-NB-tropic strain of FV was used throughout these experiments (4) . This strain is equally infectious in both DBA/2 (Fv-1") and BALB/c (Fv-1") mice . Virus preparations were made from the greatly enlarged spleens of infected BALB/c mice . 2 wk after infection the spleens were homogenized in nine times their weight of cold phosphate-buffered saline (PBS), the homogenate centrifuged slowly at 4°C to remove large particulate matter, and the supernate recentrifuged for 4 min at 7,000 g . The resulting supernate served as the basic virus preparation and was stored in small ampules at -70°C .
N--+NB-tropic Friend lymphatic leukemia virus (LLV-F) was derived from N-tropic FV by passage into newborn C57BL (Fv-1°) mice followed by blind passage in weanling Ha/ICR swiss mice (5) . Conversion to NB-tropism was afforded by five serial passages in BALB/c mice . Stocks of LLV-F were prepared as 20% perfusates of leukemic BALB/c spleens and were free of detectable spleen focus-forming activity .
Enlarged spleens were pooled, perfused with McCoy's medium containing 3% fetal calf serum, the perfusate clarified at 2400g for 10 min and stored at -196°C . Stocks of LLV-F were titrated for their helper activity for the defective spleen focus-forming component (SFFV) of FV by the method of Steeves et al . (6) and showed 8 x 10' helper U per ml .
Tumors . Tumors of FV-transformed cells were established by the method of Buffet and Furth (7) and Friend and Haddad (8) . This procedure involved subcutaneous transplantation to syngeneic hosts of washed fragments of the greatly enlarged spleens of mice infected 25-28 days earlier with N-->NB-tropic FV. Tumors of both BALB/c and BALB .B mice were established and passed serially in their respective syngeneic hosts . Tumors of BALB/c origin are referred to as HFL/d-ac ; "d" refers to the H-2 type of the mouse from which this tumor was derived ; "ac" refers to subcutaneous passage . Similarly, tumors of BALB .B origin are called HFL/b-sc .
Tissue Culture . All cell lines grown in culture were established from their respective subcutaneous solid tumors . These lines consisted of nonadherent cells maintained in suspension culture by planting 5-ml samples containing 5 x 10°cells/ml in T-30 flasks and subculturing approximately 5 days later when the cell concentration reached 5 x 1(1 8 cells/ml . The growth medium used throughout was Eagle's minimum essential medium with Earle's base (MEM-Earle's) plus 0 .58 mg/ml L-glutamine, 100 U/ml penicillin and 100 mcg/ml streptomycin supplemented with 20% fetal calf serum. Cell lines originating from BALB/c tumors are called HFL/d-tc, those of BALB .B origin, HFL/b-tc . These cell lines have been in continuous serial culture for at least 2 yr .
Virus Neutralization Assay . Immune sera were tested for FV-neutralizing activity by the method of Steeves and Axelrad (9) . Diluted sera and virus were combined at time zero and incubated at 37°C . Samples were removed from the reaction tubes at 10-or 15-min intervals for up to 40 min, appropriately diluted in ice-cold PBS, and immediately assayed in groups of seven BALB/c mice for residual virus capable of producing spleen foci . Antisera potencies were expressed in terms of the inactivation constant, K, determined from the equation K = (Dlt) Loge (V,/V,), where D = dilution of antiserum, Vo = virus titer at time zero, and t = virus titer at time t . Neutralization of LLV by immune sera was tested by the method of Steeves et al. (6) .
Antisera . Antiserum specific for the alloantigen H-2K .31 was prepared by hyperimmunization of A/J mice with cells of the methylcholanthrene-induced BALB/c sarcoma, Meth A . Anti-FV serum, containing both cytotoxic (anti-FMR) and virus-neutralizing (anti-virus envelope antigen [VEAL) activity, was prepared by hyperimmunization of BALB/c or BALB .B mice with N--)-NBtropic FV grown in syngeneic mice . Anti-HFL/d-tc was prepared by hyperimmunization of BALB/c mice with HFL/d-tc cells after regression of HFL/d-tc-produced subcutaneous tumors . Assays of these sera for cytotoxic activity were performed in the presence of guinea pig complement using appropriate s'Cr-labeled target cells (10, 11) .
Absorption of Anti-FV. For the quantitative absorption of anti-FV serum, cells were harvested, washed five times in medium 199, and resuspended to a convenient volume . The number of viable cells, determined by exclusion of trypan blue (0 .4% in normal saline), was >90% . Serial twofold dilutions of viable cells were mixed with antiserum appropriately diluted with medium 199 and incubated at 37°C with shaking for 1 h, followed by incubation at 4°C with shaking for an additional hour . The suspensions were then centrifuged at 300 g for 15 min and the resultant supernate assayed in the presence of guinea pig complement for residual cytotoxic activity toward s'Cr-labeled BALB/c spleen cells infected 7-11 days earlier with N-NB tropic FV . Tumor growth occurred only in the four normal control mice, whereas the animals previously exposed to HFL/b-tc cells showed no detectable tumor development . HFL/d-tc cells, tested through passage 100 in culture, also showed a marked capacity for inducing tumor immunity in syngeneic BALB/c hosts, although to a considerably lesser degree than that observed in BALB .B mice inoculated with HFL/b-tc cells. Subcutaneous inoculation of 106 HFL/d-tc cells in normal syngeneic hosts resulted in the development of a palpable tumor, 0.5-1 .0 cm in diameter, within 7-10 days . Table I shows that more than half of these mice appeared tumor-free 18-21 days later.
All regressor mice within each group noted in Table I were rechallenged subcutaneously, at least 16 days after tumor regression, with 106 viable HFL/dtc cells . None of these mice showed detectable tumor development, although 0 .5-1-cm tumors developed at least transiently in all normal control mice similarly inoculated . Thereafter it was possible to hyperimmunize these regressor mice with progressively increasing doses of HFL/d-tc cells (see below) .
Since both HFL/b and HFL/d cells originated from tumors induced in vivo with FV, they might both be expected to show FV-associated cell surface specificities which could function as transplantation antigens . This is particularly likely in the case of HFL/b-tc cells, since these cells produce complete, infectious FV and release it into the culture medium . HFL/d-tc cells, which produce no detectable levels of infectious FV, nevertheless possess the complete FV genome (3), the partial expression of which could result in the production of a transplantation antigen .
Viral Antigen Expression : Cell Surface Antigen (FMR) . Mice immunized
against infectious FV produce two populations of antibodies in their sera: (a) virus-neutralizing antibodies specific for VEA on the surfaces of both productively infected cells and intact progeny virus particles, and (b) cytotoxic antibodies to the cell surface antigen (CSA) present on virus-infected cells, but not present in antibody-accessible form on the surface of intact virus particles (12) . These two antibody activities are properties of two separable populations of antibodies that recognize different virus-coded polypeptides (13, 14) . The CSA specificity induced by FV cross-reacts with CSA specificities similarly induced by Moloney and Rauscher viruses, and has therefore been termed FMR (15) .
After regression of HFL/d-tc-produced solid tumors in BALB/c mice, hyperimmunization with HFL/d-tc cells did not induce the production of antibodies detectable in the complement-dependent cytotoxic assay, using guinea pig serum as a complement source . Fig . 1 illustrates that sera from such animals failed to show cytotoxic activity toward either the homologous immunogen, cultured HFL/d-tc cells, or spleen cells from FV-infected BALB/c mice. When HFL/d-tc cells taken at the 13th and 15th passages in vitro were tested directly for sensitivity to complement-mediated cytolysis by a known anti-FMR serum, these cells were completely resistant . Moreover, mechanically dispersed cells from a primary solid tumor derived by the subcutaneous implantation of HFL/dtc cells harvested at the 13th passage in vitro were also resistant to cytotoxic lysis by anti-FMR serum . In contrast, primary FV-infected syngeneic spleen We have observed a correlation betwen the expression of FV-associated antigens and the induction of transplantation immunity. HFL/b-tc cells produce complete, infectious FV which is released into the culture medium, and their cell surfaces bear both VEA and FMR antigenic specificities . Either or both of these specificities might act as transplantation antigens . HFL/d-tc cells, on the other hand, make no detectable level of infectious FV and do not express the FMR antigen. Thus, the absence of an important viral antigen correlates with the lower capacity of HFL/d-tc cells to induce transplantation immunity. Furthermore, HFL/d-tc cells, which expressed Friend VEA for more than a 100 passages in culture, ceased to express this antigen at a point in time that coincided with the observation of a marked further decrease in the capacity of the cells to induce transplantation immunity in syngeneic hosts. These facts make a circumstantial case for the interpretation that HFL/b cells are more immunogenic than HFL/d cells because they express more viral antigens .
There is no evidence from the present experiments directly implicating the relative immune responsiveness of BALB/c vs. BALB.B mice to FV-associated tumor antigens . However, in unpublished studies in our laboratory, killer cells specific for FV-infected target cells have been detected among the peritoneal exudate population from BALB.B mice immunized with HFL/b-tc cells. Such killer cells have not been detected to date in BALB/c mice immunized with HFL/d-tc cells. This finding might reflect a difference betwen BALB.B and BALB/c mice in specific immune responsiveness to a particular cell surface antigen.
Previous studies in our laboratory (16) is not yet possible to infer on statistical grounds that the difference in H2 genotype is responsible for these phenotypic differences. However, since these findings with tumor cell lines grown in vitro are consistent with our earlier findings in vivo (16) , the hypothesis that the H2 difference is a major causal factor seems reasonable . These earlier studies in vivo further indicated that antigen H-2K.31, like FMR, also showed a markedly decreased expression on FV-infected BALB/c spleen cells in the late stages of the disease syndrome. This finding may suggest some molecular interaction between the H-2 molecule and virus-associated molecules similar to the interaction suggested by recent studies with lymphocytic choriomeningitis virus (17) .
Nonproducer Thus the HFL/d-tc cell line has gone through three distinct phases in its 2-yr passage history. During its very early passages, it produced small but demonstrable amounts of complete FV (3) ; after about 14 passages in culture, it ceased making any detectable level of infectious virus, and was found to be phenotypically FMR-negative, VEA-positive, and gp69/71-positive . More than 1 yr later (125 serial passages in culture) it changed again, becoming VEA-negative and gp69/71-negative . 
